Shinichiro Iida
Overview
Explore the profile of Shinichiro Iida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
378
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang J, Toyozum T, Kano M, Matsumoto Y, Otsuka R, Sekino N, et al.
Oncology
. 2025 Mar;
:1-17.
PMID: 40068649
Background: Esophageal squamous cell carcinoma (ESCC) is one of the most malignant cancers in the world, which seriously affects the survival and quality of life of patients. Aberrant expression of...
2.
Matsumoto Y, Otsuka R, Nishioka Y, Toyozumi T, Sekino N, Shiraishi T, et al.
Oncology
. 2025 Jan;
:1-10.
PMID: 39870059
Introduction: Esophageal squamous cell carcinoma (ESCC) has one of the poorest cancer prognosis rates; there is an urgent need to develop new drug therapies and biomarkers. CD63, a tetraspanin protein...
3.
Iida S, Matsumoto Y, Toyozumi T, Otsuka R, Shiraishi T, Morishita H, et al.
Cancer Diagn Progn
. 2024 Nov;
4(6):754-761.
PMID: 39502618
Background/aim: Although the impact of body composition on cancer treatment outcomes of patients with cancer has been increasingly reported, it is still unclear whether the radiodensity of subcutaneous adipose tissue...
4.
Morishita H, Otsuka R, Toyozumi T, Matsumoto Y, Sekino N, Okada K, et al.
Cancer Diagn Progn
. 2024 Nov;
4(6):762-768.
PMID: 39502604
Background/aim: Identifying prognostic and molecular markers as therapeutic targets for esophageal squamous cell carcinoma (ESCC) could enhance the efficacy of multidisciplinary treatments. While tissue expression of sirtuin 1 (SIRT1) has...
5.
Hu J, Toyozumi T, Murakami K, Endo S, Matsumoto Y, Otsuka R, et al.
Cancer Med
. 2024 Sep;
13(17):e70179.
PMID: 39264227
Background: Tumor cells (TC) participate in tumor progression by altering the immune responses in the tumor microenvironment. However, the clinical relevance and prognostic effect of PD-L1 expression and tumor-infiltrating lymphocytes...
6.
Morishita H, Otsuka R, Murakami K, Endo S, Toyozumi T, Matsumoto Y, et al.
Oncology
. 2024 Jul;
102(11):960-968.
PMID: 38972308
Introduction: Identifying accurate biomarkers for predicting response to chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC) is a critical challenge. The protein SIRT1, recognized for its implications in...
7.
Nishioka Y, Matsumoto Y, Murakami K, Endo S, Toyozumi T, Otsuka R, et al.
Oncol Lett
. 2024 Jun;
28(2):360.
PMID: 38881709
Small bowel adenocarcinoma (SBA) is a rare tumor with a poor prognosis. Due to its rarity, the research infrastructure for SBA, including cell lines, is inadequate. The present study established...
8.
Maiyulan A, Matsumoto Y, Wang H, Murakami K, Toyozumi T, Otsuka R, et al.
Oncol Lett
. 2024 Jun;
28(1):334.
PMID: 38827568
Despite advances in treatment and diagnosis, the prognosis of patients with esophageal squamous cell carcinoma (ESCC) remains poor. MicroRNAs (miRNAs/miRs) are associated with prognosis in esophageal cancer, indicating that they...
9.
Matsumoto Y, Iida S, Kano M, Suito H, Hayashi H, Hayano K, et al.
Asian J Endosc Surg
. 2024 Feb;
17(2):e13282.
PMID: 38407569
As the number of bariatric and metabolic surgeries being performed is increasing, the importance of revision surgeries is escalating. In this report, we describe a case of revision surgery performed...
10.
Sasaki T, Matsumoto Y, Murakami K, Endo S, Toyozumi T, Otsuka R, et al.
Esophagus
. 2023 Apr;
20(4):691-703.
PMID: 37086309
Purpose: The gut microbiome plays an important role in cancer pathogenesis and therapy. Some studies have reported that specific bacteria in tumor tissues may contribute to the prognosis and treatment...